ライフサイエンスコーパス: mastectomy

1 ion is increasingly performed at the time of mastectomy.

2 ant treatment option for patients undergoing mastectomy.

3 reast cancer, many women continue to undergo mastectomy.

4 dely clear margins is common and may lead to mastectomy.

5 with early-stage breast cancer who underwent mastectomy.

6 ubtypes) with breast conservation therapy or mastectomy.

7 ction to decrease breast complications after mastectomy.

8 but 31% of BCT-eligible patients still chose mastectomy.

9 ectomy, breast reconstruction, and bilateral mastectomy.

10 total of 35.5% of the study cohort underwent mastectomy.

11 underwent breast-conserving surgery (BCS) or mastectomy.

12 s and reexcision among patients with partial mastectomy.

13 03-1.29) influenced axillary evaluation with mastectomy.

14 fter surgeons had completed standard partial mastectomy.

15 l after breast conservation therapy (BCT) vs mastectomy.

16 on lumpectomy and 28,267 (37.9%) underwent a mastectomy.

17 breast cancer detected during a prophylactic mastectomy.

18 breast cancer (58.3%) underwent a bilateral mastectomy.

19 clinical course of treatment by conducting a mastectomy.

20 ived it, while 16 patients (32.7%) underwent mastectomy.

21 ims to identify receipt of RT and subsequent mastectomy.

22 onstructive surgery with patients undergoing mastectomy.

23 ogous IR, DR, and SR breast procedures after mastectomy.

24 over time and are now similar to those after mastectomy.

25 th invasive breast cancer undergoing planned mastectomy.

26 s, and 25 cancers discovered at prophylactic mastectomy.

27 herapy decreases the likelihood of LRR after mastectomy.

28 event for breast cancer patients undergoing mastectomy.

29 Contralateral prophylactic mastectomy.

30 mastectomies, and contralateral prophylactic mastectomies.

31 tients (5%) underwent bilateral prophylactic mastectomy; 1,004 chose surveillance with (n = 173) or w

32 s no-MRI (referent) were as follows: initial mastectomy 16.4% versus 8.1% [OR, 2.22 (P < 0.001); adju

33 ) underwent BCS while 9011 (25.3%) underwent mastectomy; 17.7% undergoing BCS and 63.0% undergoing ma

34 Rates of ALND decreased in women undergoing mastectomy (2006, 20.0%; 2012, 10.7%) and BCS (2006, 1.2

35 axillary evaluation increased over time with mastectomy (2006, 56.6%; 2012, 67.4%) and were relativel

36 .87); adjusted OR, 0.95 (P = 0.71)]; overall mastectomy 25.5% versus 18.2% [OR, 1.54 (P < 0.001); adj

37 and less likely to undergo modified radical mastectomy (25% vs 47% of the Pt/PhysD breast cancer pat

38 ata that included 28,176 women who underwent mastectomy (25,141 mastectomy alone and 3,035 IBR) betwe

39 n: 593 were reexcisions (14.4%) and 132 were mastectomies (3.2%).

40 cer (ILC), outcomes were as follows: initial mastectomy 31.1% versus 24.9% [OR, 1.36 (P = 0.056); adj

41 031); adjusted OR, 0.56 (P = 0.09)]; overall mastectomy 43.0% versus 40.2% [OR, 1.12 (P = 0.45); adju

42 en with Medicaid were more likely to receive mastectomy (60% vs 39%, P < .05).

43 Of 891 mastectomies, 65% (580/891) had immediate implant, 11% (

44 After mastectomy, 73.4% of the patients in both groups underwe

45 e hernia repairs (15.7%), bariatric (10.5%), mastectomy (9.7%), and cholecystectomy (9.0%).

46 uding the cancers discovered at prophylactic mastectomy (95% confidence interval: 69.5%, 82.4%) and 9

47 at more than 24 months, 28 (6.4%) underwent mastectomy (all benign), and 68 (15.6%) had lesion upgra

48 a higher survival rate than those undergoing mastectomy alone (hazard ratio, 1.31; P < .001) or maste

49 3 or greater (HR 1.94, 95% CI 1.04-3.63) or mastectomy alone (HR 2.14, 95% CI 1.26-3.63).

50 ficantly increased odds of IBR compared with mastectomy alone (odds ratio [OR], 1.71; 95% CI, 1.47 to

51 tly farther compared with those who received mastectomy alone (OR, 1.04; 95% CI, 1.02 to 1.05 for eve

52 8,176 women who underwent mastectomy (25,141 mastectomy alone and 3,035 IBR) between April 1, 2002, a

53 rvival rate compared with those treated with mastectomy alone or mastectomy with radiation for early-

54 n therapy was used to treat 70% of patients, mastectomy alone was used to treat 27% of patients, and

55 vival rates of patients who underwent BCT, a mastectomy alone, or a mastectomy with radiation were 97

56 of local therapy, breast-conserving therapy, mastectomy alone, or mastectomy followed by postmastecto

57 invasive ductal carcinoma treated with BCT, mastectomy alone, or mastectomy with radiation during th

58 Breast conservation therapy, mastectomy alone, or mastectomy with radiation.

59 o breast cancer for patients undergoing BCT, mastectomy alone, or mastectomy with radiation.

60 immediate breast reconstruction compared to mastectomy alone.

61 increase the risk of lymphedema compared to mastectomy alone.

62 Receipt of bilateral mastectomy also increased: from 3% in 1998 to 18% in 200

63 lumpectomy and radiation and underwent fewer mastectomies and less chemotherapy than patients with ca

64 estionnaires; of those eligible, 3,977 had a mastectomy and 1,598 reported receipt of CPM.

65 eceived CPM, while 45.8% received unilateral mastectomy and 22.8% received breast conservation surger

66 or patients who suffer from lymphedema after mastectomy and axillary dissection.

67 iopsy confirmed breast cancer, she underwent mastectomy and axillary node dissection for a left-sided

68 iopsy confirmed breast cancer, she underwent mastectomy and axillary node dissection for a left-sided

69 Although mastectomy and breast conserving surgery have low risk f

70 i-institutional study of patients undergoing mastectomy and breast conserving surgery was performed f

71 s incur potential morbidity, especially when mastectomy and breast reconstruction are done for widesp

72 Women undergoing mastectomy and breast reconstruction for unilateral brea

73 ve review of all patients undergoing partial mastectomy and concurrent reduction mammoplasty performe

74 Breast reconstruction at any time after mastectomy and patient satisfaction with different aspec

75 and receipt of RT were predictive of time to mastectomy and were incorporated into the nomogram.

76 ew board approval, patients undergoing total mastectomy and/or axillary lymph node dissection were ra

77 lumpectomy, unilateral mastectomy, bilateral mastectomy) and rates of additional surgery after initia

78 mary surgery (breast-conservation surgery or mastectomy), and tumour bed boost radiotherapy.

79 Most NAC recipients (68.4%) had mastectomies, and 14.3% of them underwent BLM.

80 illary investigations, wait time to surgery, mastectomies, and contralateral prophylactic mastectomie

81 nserving surgery, 33.4% underwent unilateral mastectomy, and 7.0% underwent CPM.

82 nserving surgery, 33.4% underwent unilateral mastectomy, and 7.0% underwent CPM.

83 rgoing breast-conserving surgery, unilateral mastectomy, and CPM.

84 rgoing breast-conserving surgery, unilateral mastectomy, and CPM.

85 ss than 2 mm alone are not an indication for mastectomy, and factors known to impact rates of IBTR sh

86 lthough this was at the expense of increased mastectomies-and overall patient benefit from MRI in ILC

87 Medical indications for mastectomy are well defined and present in a minority of

88 pingo-oophorectomy (RRBSO) and risk-reducing mastectomy are widely used for BRCA1 and BRCA2 mutation

89 Mastectomies as first salvage treatment for ipsilateral

90 ts (9.6%) underwent a bilateral prophylactic mastectomy at a median of 23 months following EOC diagno

91 e cross-sectional study of patients planning mastectomy at a single site, over 20 months.

92 Of 485 patients reporting mastectomy at the initial survey and remaining disease f

93 diotherapy use for DCIS had increased use of mastectomy at the time of a second breast event even amo

94 h greater disease burden or those undergoing mastectomy, axillary dissection remains standard managem

95 The rate of positive margins after partial mastectomy (before randomization) was similar in the sha

96 and those undergoing bilateral prophylactic mastectomies between 1980 and 2009.

97 atients with breast cancer who underwent 891 mastectomies between 2005 and 2013 were prospectively sc

98 l surgical procedure (lumpectomy, unilateral mastectomy, bilateral mastectomy) and rates of additiona

99 sting and the impact of results on bilateral mastectomy (BLM) use.

100 , breast conserving surgery (BCS), bilateral mastectomy (BLM), and unilateral mastectomy (ULM) was ab

101 o local or regional recurrence, frequency of mastectomy, breast cancer-specific survival, time to dis

102 portions of BCS-eligible patients undergoing mastectomy, breast reconstruction, and bilateral mastect

103 patients (4.9%) had a subsequent completion mastectomy, but no difference was found in the type of r

104 After mastectomy chest-wall radiotherapy was associated with i

105 less than 2 cm, 11% with Medicaid underwent mastectomy compared with 47% with PI (P < .05).

106 patients choosing contralateral prophylactic mastectomy, complications and procedure extent may be un

107 e growing rate of contralateral prophylactic mastectomy (CPM) among women diagnosed as having breast

108 process regarding contralateral prophylactic mastectomy (CPM) among women with sporadic breast cancer

109 ients who undergo contralateral prophylactic mastectomy (CPM) and breast reconstruction.

110 emporal trends in contralateral prophylactic mastectomy (CPM) and determine whether survival differed

111 KGROUND: Rates of contralateral prophylactic mastectomy (CPM) have increased dramatically, particular

112 lines assert that contralateral prophylactic mastectomy (CPM) should be discouraged in patients witho

113 Contralateral prophylactic mastectomy (CPM) use is increasing among women with unil

114 The use of contralateral prophylactic mastectomies (CPMs) among patients with invasive unilate

115 The rate of contralateral prophylactic mastectomies (CPMs) continues to rise, although there is

116 oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up.

117 k women and mutation carriers, risk-reducing mastectomy decreased breast cancer by 85% to 100% and br

118 ter mastectomy was considered delayed if the mastectomy did not include IR or secondary if the mastec

119 pe of surgery performed-breast-conserving or mastectomy-did not influence rates of LR and RR.

120 tic appearance and self-confidence following mastectomy due to breast cancer.

121 ast-conserving therapy, mastectomy alone, or mastectomy followed by postmastectomy radiation therapy

122 Partial mastectomy followed by whole breast radiation is breast-

123 dditional mammography (NX), one was found at mastectomy for another cancer (N0), and one was found at

124 Most women undergoing mastectomy for breast cancer do not undergo breast recon

125 bed complications in 14,894 women undergoing mastectomy for breast cancer from 1998 to 2007 and who u

126 reexcision among patients undergoing partial mastectomy for breast cancer.

127 Immediate breast reconstruction (IBR) after mastectomy for cancer has increased in recent years, yet

128 t study of temporal trends in performance of mastectomy for early-stage breast cancer using multivari

129 t for prophylactic mastectomy or therapeutic mastectomy for in situ breast cancer (78.6%; P < .001).

130 .05) and were more likely to be treated with mastectomy for larger tumors compared with women with PI

131 therapy provides an appealing alternative to mastectomy for many women.

132 onservation is therapeutically equivalent to mastectomy for most patients with early-stage breast can

133 ever, women with PI were more likely to have mastectomy for smaller tumors; among women with tumors l

134 ology clinic among women planning to undergo mastectomy for stage I to III invasive ductal or lobular

135 oved outcomes, increasing rates of bilateral mastectomy for unilateral cancer have been observed in t

136 Rates of bilateral mastectomy for unilateral disease increased from 1.9% in

137 rends in breast reconstruction and bilateral mastectomy for unilateral disease.

138 with stage I to III breast cancer undergoing mastectomy from 2000 through 2011.

139 ncluded women aged 18 to 64 years undergoing mastectomy from January 1, 2004, through December 31, 20

140 y; 17.7% undergoing BCS and 63.0% undergoing mastectomy had an axillary evaluation.

141 Patients undergoing mastectomy had larger tumors and higher proportions of p

142 the number of women undergoing risk-reducing mastectomy has increased rapidly in the USA in the past

143 such as soft tissue reconstruction following mastectomy; however, the ability of tumors to commandeer

144 mortality difference compared with bilateral mastectomy (HR, 1.02 [95% CI, 0.94-1.11]; 10-year mortal

145 in patients with these tumor features having mastectomy if the need for postmastectomy radiotherapy i

146 nserving therapy was performed in 656 (39%), mastectomy in 297 (17%) and mastectomy + postmastectomy

147 A minority of patients undergoing mastectomy in a single academic center made a high-quali

148 The adjusted odds of mastectomy in BCS-eligible women increased 34% during th

149 garding BCT was consistently documented, and mastectomy in BCT-eligible patients was largely the resu

150 ere seen in the trials of radiotherapy after mastectomy in node-positive disease (rate ratios, breast

151 I, 0.62 to 0.65), whereas radiotherapy after mastectomy in node-positive disease was associated with

152 ecent shift toward increasing performance of mastectomy in patients eligible for BCS.

153 one was found at prophylactic contralateral mastectomy in the same patient (NX).

154 s of radiotherapy for DCIS affect the use of mastectomy in these patients.

155 Women undergoing mastectomy in this sample were highly involved in decisi

156 ctomy did not include IR or secondary if the mastectomy included IR.

157 A mastectomy, including post-anaesthesia recovery and inpa

158 mong 189,734 patients, the rate of bilateral mastectomy increased from 2.0% (95% CI, 1.7%-2.2%) in 19

159 Use of bilateral mastectomy increased significantly throughout California

160 perience a second breast event, many undergo mastectomy instead.

161 Evidence indicates that increasing use of mastectomy is a patient-driven trend that is most pronou

162 Bilateral mastectomy is increasingly used to treat unilateral brea

163 l breast cancer, contralateral risk-reducing mastectomy is often, but not universally, indicated.

164 harp increase in contralateral risk-reducing mastectomy is surprising.

165 Partial mastectomy is the most commonly performed procedure for

166 fit of testosterone therapy (with or without mastectomy) is a reduced risk of breast cancer.

167 erentially around the cavity left by partial mastectomy) may reduce the rates of positive margins (ma

168 ients undergoing contralateral risk-reducing mastectomy might not be categorised as high risk and the

169 ith additional procedure matching: bilateral mastectomy, nodal surgery, tissue, and/or implant.

170 Mastectomy only and mastectomy with reconstruction.

171 6.2%) and did not differ by treatment group (mastectomy only, 55.2% [15.0%]; mastectomy with reconstr

172 my only; 39 of these women (47.6%) underwent mastectomy only.

173 7%) had a calculated treatment preference of mastectomy only; 39 of these women (47.6%) underwent mas

174 ed for this study, including 6 who underwent mastectomy or axillary node dissection.

175 Cohort characteristics were grouped by mastectomy or BCS.

176 ed that receipt of CPM (vs either unilateral mastectomy or breast conservation surgery) was significa

177 ed node-negative breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the S

178 unilateral breast cancer who had undergone a mastectomy or lumpectomy with clear surgical margins.

179 d the increase was greatest for prophylactic mastectomy or therapeutic mastectomy for in situ breast

180 58 ex vivo samples from patients undergoing mastectomy or wide local excision, we demonstrate the pe

181 .7; P < .001), patients undergoing bilateral mastectomy (OR, 0.5; P < .001), or patients in the highe

182 % CI, 1.62-1.85), contralateral prophylactic mastectomy (OR, 1.48; 95% CI, 1.23-1.77), and a greater

183 tatic disease (OR, 1.51; 95% CI, 1.42-1.61), mastectomy (OR, 1.73; 95% CI, 1.62-1.85), contralateral

184 self-report, categorized as CPM, unilateral mastectomy, or breast conservation surgery.

185 tion (breast-conserving therapy), unilateral mastectomy, or CPM, with subsequent subgroup analysis st

186 tion (breast-conserving therapy), unilateral mastectomy, or CPM, with subsequent subgroup analysis st

187 2 (51.2%) of 160 noncarriers chose bilateral mastectomy (P < .001).

188 ed by a decrease in unilateral and bilateral mastectomy (P = .002).

189 Women who had a partial mastectomy (P=0.028), had a higher educational level (P=

190 logic nodal status/breast tumor response; in mastectomy patients, they were clinical tumor size (befo

191 ients compared with only 16.0% of unilateral mastectomy patients, with rates of reconstruction with C

192 ients compared with only 16.0% of unilateral mastectomy patients, with rates of reconstruction with C

193 Conclusion At 1 year after mastectomy, patients who underwent autologous reconstruc

194 intestinal tract endoscopy (PFS, 26.5-34.3), mastectomy (PFS, 16.5-35.0), inguinal hernia repair (PFS

195 shave margins (CSM) versus standard partial mastectomy (PM) in patients with breast cancer.

196 undergoing 5 outpatient procedures: partial mastectomy (PM), partial mastectomy with sentinel lymph

197 clinical factors, surgical approach (partial mastectomy [PM] or total mastectomy [TM]), and BCT failu

198 ed in 656 (39%), mastectomy in 297 (17%) and mastectomy + postmastectomy radiation therapy in 744 (44

199 C should not be the sole indication for post-mastectomy radiation, and accelerated delivery methods f

200 r nearly all previously irradiated skin plus mastectomy ("radical").

201 A lower overall salvage mastectomy rate after LR was observed in the LE+RT group

202 rved in 78% to 93%, resulting in a 3% to 16% mastectomy rate.

203 To study the impact of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) re

204 ence showed that MRI significantly increased mastectomy rates and suggests an unfavorable harm-benefi

205 Mastectomy rates do not yet exceed current American Canc

206 dy examined the effect of insurance payer on mastectomy rates of 1539 women treated within a single h

207 y and is associated with positive margin and mastectomy rates that are low irrespective of the presen

208 surgical outcome (positive margin rates and mastectomy rates) of women with breast cancer who underw

209 , and surgical outcomes (positive margin and mastectomy rates) were investigated.

210 In women undergoing mastectomy, rates of breast reconstruction increased fro

211 1, 2016, at the 11 sites associated with the Mastectomy Reconstruction Outcomes Consortium Study.

212 Breast-conserving therapy (BCT) and mastectomy result in equivalent long-term survival.

213 skin dimpling, and skin discoloration of the mastectomy scar and radiation bed.

214 egional lymph nodes, followed by an optional mastectomy scar boost of four fractions of 3.33 Gy.

215 At the time of mastectomy, she is found to have several foci of residua

216 Prophylactic mastectomy should be considered on an individual basis g

217 Women with SLN metastases who will undergo mastectomy should be offered ALND.

218 Women with SLN metastases who will undergo mastectomy should be offered ALND.

219 n of the ROIs was significantly lower at the mastectomy site compared to the natural breast (p<0.01).

220 ndomly cued to palpate their natural breast, mastectomy site or breast reconstruction, and external s

221 g BCS and uncertainty regarding its use with mastectomy, SLNB or ALND is performed frequently.

222 breast cancer was detected in a prophylactic mastectomy specimen.

223 iffuse reflectance spectra of lumpectomy and mastectomy specimens using a Monte Carlo model.

224 ng and not including cancers in prophylactic mastectomy specimens, respectively).

225 on breast tissues excised from prophylactic mastectomy specimens.

226 Beyond prophylactic mastectomy, there are currently very few options availab

227 en considered an indication for undergoing a mastectomy, this dictum may not apply in women with brea

228 e were no significant differences in time to mastectomy, time to distant metastasis, breast cancer-sp

229 l approach (partial mastectomy [PM] or total mastectomy [TM]), and BCT failure (initial PM followed b

230 on carriers) frequently undergo prophylactic mastectomy to minimize their risk of breast cancer.

231 mong all patients undergoing initial partial mastectomy, total mastectomy was performed in 190 patien

232 re (including diagnostics, chemotherapy, and mastectomy) totalled US$1393.

233 , bilateral mastectomy (BLM), and unilateral mastectomy (ULM) was abstracted from the medical records

234 r treatments combined, (2) CPM vs unilateral mastectomy (UM), and (3) CPM vs breast-conserving surger

235 Contralateral prophylactic mastectomy use is substantial among patients without cli

236 Mastectomy vs BCS at a second breast event defined as DC

237 r DCIS increased the likelihood of receiving mastectomy vs BCS at a subsequent breast event, even amo

238 ty, 16.8% [95% CI, 16.6%-17.1%]), unilateral mastectomy was associated with higher all-cause mortalit

239 Unilateral mastectomy was associated with higher mortality than wer

240 In M0 patients, mastectomy was associated with worse survival outcomes c

241 Reconstruction more than 7 days after mastectomy was considered delayed if the mastectomy did

242 Reconstruction within 7 days of mastectomy was considered immediate.

243 Five-year incidence of subsequent mastectomy was higher in women treated with brachytherap

244 Bilateral mastectomy was more often used by non-Hispanic white wom

245 95% CI, 1.04-1.22]); in contrast, unilateral mastectomy was more often used by racial/ethnic minoriti

246 Mastectomy was once the gold standard for the treatment

247 Mastectomy was performed in 1464 patients and breast-con

248 Mastectomy was performed in 17293 women (mean [SD] age,

249 undergoing initial partial mastectomy, total mastectomy was performed in 190 patients (8.5%; 95% CI,

250 Mastectomies were categorized as immediate implant, imme

251 A total of 48,393 mastectomies were performed during the study period, of

252 Adjusted odds ratios for receiving mastectomy were 1.43 (95% CI, 1.10-1.85) and 1.90 (95% C

253 ysis, 490 women (1370 screenings) with prior mastectomy were excluded.

254 ergoing no secondary procedures unrelated to mastectomy were included.

255 Patients receiving bilateral mastectomy were more likely to receive reconstruction (o

256 patients undergoing unilateral or bilateral mastectomy were recorded.

257 n increasing number of patients are pursuing mastectomy, which may be followed by breast reconstructi

258 vised placement of an implant at the time of mastectomy while Surgeon B contrasted the pros and cons

259 ents with positive sentinel nodes undergoing mastectomy (who do not, as a standard, receive adjuvant

260 al carcinoma in situ (DCIS) who will undergo mastectomy, who previously underwent breast and/or axill

261 h ductal carcinoma in situ, who will undergo mastectomy, who previously underwent breast and/or axill

262 Thirty-eight underwent mastectomy/wide excision with partial skin resection ("c

263 In contrast, 47.9% aCT patients had mastectomies with 7.3% BLM.

264 ther unilateral (47.2%) or bilateral (52.8%) mastectomies with reconstruction.

265 r presenting for breast reconstruction after mastectomy with 2 years or more of follow-up.

266 bidity were decreased in patients undergoing mastectomy with and without immediate breast reconstruct

267 Her breast surgeon recommended a right mastectomy with axillary node dissection.

268 of patients for whom RT could be avoided or mastectomy with breast reconstruction is indicated.

269 o its independent effects on morbidity after mastectomy with immediate breast reconstruction are limi

270 ve cohort study of adult women who underwent mastectomy with immediate breast reconstruction from 200

271 All women undergoing mastectomy with or without immediate breast reconstructi

272 upports the safety of NC in women undergoing mastectomy with or without immediate breast reconstructi

273 nt chemotherapy for surgical morbidity after mastectomy with or without reconstruction using 1:1 matc

274 tomy alone (hazard ratio, 1.31; P < .001) or mastectomy with radiation (hazard ratio, 1.47; P < .001)

275 inoma treated with BCT, mastectomy alone, or mastectomy with radiation during the period from 1998 to

276 with those treated with mastectomy alone or mastectomy with radiation for early-stage invasive ducta

277 alone was used to treat 27% of patients, and mastectomy with radiation was used to treat 3% of patien

278 who underwent BCT, a mastectomy alone, or a mastectomy with radiation were 97%, 94%, and 90%, respec

279 t conservation therapy, mastectomy alone, or mastectomy with radiation.

280 atients undergoing BCT, mastectomy alone, or mastectomy with radiation.

281 tment group (mastectomy only, 55.2% [15.0%]; mastectomy with reconstruction, 60.5% [16.5%]).

282 Among patients receiving mastectomy with reconstruction, reconstruction type and

283 specifically, within the subgroup undergoing mastectomy with reconstruction, using multivariable line

284 Mastectomy only and mastectomy with reconstruction.

285 similar after breast conservation and after mastectomy with reconstruction.

286 3 mastectomy without reconstruction, and 222 mastectomy with reconstruction.

287 ast conservation therapy and those receiving mastectomy with reconstruction.

288 ruction; 36 of these women (87.8%) underwent mastectomy with reconstruction.

289 5%) had a calculated treatment preference of mastectomy with reconstruction; 36 of these women (87.8%

290 aluate whether an approach combining partial mastectomy with reduction mammoplasty could provide a sa

291 procedures: partial mastectomy (PM), partial mastectomy with sentinel lymph node biopsy (PM SLNB), la

292 l cohort included 15,154 women who underwent mastectomy with tissue expander (TE: 70.5%), autologous

293 e were 2983 patients who underwent segmental mastectomy with whole-breast irradiation from 1987 to 20

294 f stage 0 to III who were undergoing partial mastectomy, with or without resection of selective margi

295 She underwent partial mastectomy, with partial axillary node dissection and se

296 of overall morbidity in the group undergoing mastectomy without breast reconstruction (odds ratio [OR

297 mplete sample (OR, 0.59; 95% CI, 0.49-0.71), mastectomy without breast reconstruction (OR, 0.59; 95%

298 er overall morbidity in the group undergoing mastectomy without breast reconstruction (OR, 0.61; 95%

299 overall morbidity in the patients undergoing mastectomy without breast reconstruction and in those un

300 Of 85,851 women, 66,593 (77.6%) underwent mastectomy without breast reconstruction, with 2876 (4.3

301 963 underwent breast-conserving surgery, 263 mastectomy without reconstruction, and 222 mastectomy wi